Liora Ter Horst

Research activity per year

If you made any changes in Pure these will be visible here soon.

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Vlaar, A. P. J., de Bruin, S., Busch, M., Timmermans, S. A. M. E. G., van Zeggeren, I. E., Koning, R., Ter Horst, L., Bulle, E. B., van Baarle, F. E. H. P., van de Poll, M. C. G., Kemper, E. M., van der Horst, I. C. C., Schultz, M. J., Horn, J., Paulus, F., Bos, L. D., Wiersinga, W. J., Witzenrath, M., Rueckinger, S., Pilz, K. & 6 others, Brouwer, M. C., Guo, R-F., Heunks, L., van Paassen, P., Riedemann, N. C. & van de Beek, D., Dec 2020, In: The Lancet Rheumatology. 2, 12, p. e764-e773
Research output: Contribution to journal › Article › Academic › peer-review